A fundamental question is whether physiological variations in metabolite levels influence stem-cell fate, tissue homeostasis and tumour suppression. Genetic changes in metabolic enzymes can alter stemcell function 1 and cause oncogenic transformation 2 . Dietary changes alter stem-cell function in multiple systems by regulating signalling, for example by insulin and/or IGF 3 . It is generally unknown whether dietary changes alter stem-cell function by changing metabolite levels; however, muscle stem-cell ageing is regulated by changes in NAD + levels 4 . Differentiation in vivo is accompanied by metabolic changes 5 , and experimental manipulation of metabolite levels in culture can modulate pluripotent stem-cell differentiation [6] [7] [8] . However, it is unclear whether physiological variation in metabolite levels influences stemcell fate in vivo.
A fundamental question is whether physiological variations in metabolite levels influence stem-cell fate, tissue homeostasis and tumour suppression. Genetic changes in metabolic enzymes can alter stemcell function 1 and cause oncogenic transformation 2 . Dietary changes alter stem-cell function in multiple systems by regulating signalling, for example by insulin and/or IGF 3 . It is generally unknown whether dietary changes alter stem-cell function by changing metabolite levels; however, muscle stem-cell ageing is regulated by changes in NAD + levels 4 . Differentiation in vivo is accompanied by metabolic changes 5 , and experimental manipulation of metabolite levels in culture can modulate pluripotent stem-cell differentiation [6] [7] [8] . However, it is unclear whether physiological variation in metabolite levels influences stemcell fate in vivo.
Studies of stem-cell metabolism have been limited by the fact that metabolomics is typically performed using millions of cells and it is generally impossible to isolate that many stem cells directly from tissues. Metabolomics has been performed on haematopoietic stem/ progenitor cells either by isolating large numbers of heterogeneous Lineage 
Kit
+ (LSK) cells 9 or by pooling HSCs from 120 mice to perform a single experiment 10 . Others have studied stem-cell metabolism by characterizing the phenotypes of knockout mice or metabolism in culture 11 . However, it has been difficult to routinely compare metabolite levels within rare cell populations in tissues. To address this we have optimized the sensitivity of metabolomics.
Metabolomics in rare cell populations
We performed metabolomics in rare cell populations by combining rapid cell isolation by flow cytometry with liquid chromatographymass spectrometry (Extended Data Fig. 1a ). Cells were kept cold during cell purification and the levels of most metabolites remained stable during cell purification (Extended Data Fig. 1b-f ). We detected approxi mately 60 metabolites, covering a range of metabolic pathways, from 10,000 HSCs (Extended Data Fig. 2a ).
We compared CD150 (Fig. 1a) . HSCs and MPPs did not differ in the metabolites that we measured (Extended Data Fig. 2b ), but did differ from all restricted progenitor populations (Fig. 1a) . Almost all of the metabolites that we detected had distinct enrichment patterns for different cell types (Extended Data Fig. 2c, d ). Therefore, even linearly related cells within a similar in vivo environment exhibit metabolic differences.
One of the most enriched metabolites in HSCs and MPPs was ascorbate (vitamin C) (Extended Data Fig. 2c ). Ascorbate remained stable during cell purification (Extended Data Fig. 1g ). Ascorbate levels were 2-to 20-fold higher in the mixed population of HSCs and MPPs (hereafter HSCs/MPPs) compared to other haematopoietic progenitors, and decreased with differentiation (Fig. 1b) .
Ascorbate regulates HSC frequency
Humans obtain ascorbate exclusively through their diet, but mice and most other mammals synthesize ascorbate in the liver using the enzyme gulonolactone oxidase (Gulo) 12 . Ascorbate is taken up by most cells through two dedicated transporters encoded by Slc23a1 and Slc23a2 (ref. 12) . Slc23a2 was expressed by most haematopoietic cells, but at 14-fold higher levels in HSCs/MPPs compared to restricted haematopoietic progenitors (Fig. 1c) . Slc23a2 expression, similar to ascorbate levels, decreased with differentiation (Fig. 1c) . Ascorbate levels in haematopoietic cells correlated strongly with Slc23a2 expression (R 2 = 0.94) (Extended Data Fig. 3a ). Slc23a1 and Gulo are not expressed by haematopoietic cells 13 . Therefore, ascorbate accumulation in HSCs was probably due to high Slc23a2 expression.
To test whether ascorbate regulates HSC function we analysed Gulo −/− mice, which are unable to synthesize ascorbate and, like humans, obtain ascorbate exclusively through their diet. Gulo −/− mice, born to Gulo +/− females, were developmentally normal and received Stem-cell fate can be influenced by metabolite levels in culture, but it is not known whether physiological variations in metabolite levels in normal tissues regulate stem-cell function in vivo. Here we describe a metabolomics method for the analysis of rare cell populations isolated directly from tissues and use it to compare mouse haematopoietic stem cells (HSCs) to restricted haematopoietic progenitors. Each haematopoietic cell type had a distinct metabolic signature. Human and mouse HSCs had unusually high levels of ascorbate, which decreased with differentiation. Systemic ascorbate depletion in mice increased HSC frequency and function, in part by reducing the function of Tet2, a dioxygenase tumour suppressor. Ascorbate depletion cooperated with Flt3 internal tandem duplication (Flt3 ITD ) leukaemic mutations to accelerate leukaemogenesis, through cell-autonomous and possibly non-cell-autonomous mechanisms, in a manner that was reversed by dietary ascorbate. Ascorbate acted cell-autonomously to negatively regulate HSC function and myelopoiesis through Tet2-dependent and Tet2-independent mechanisms. Ascorbate therefore accumulates within HSCs to promote Tet activity in vivo, limiting HSC frequency and suppressing leukaemogenesis.
Article reSeArcH ascorbate from their mothers until they were weaned at four weeks of age. They subsequently became ascorbate depleted when maintained on a standard mouse diet, which contains very little ascorbate. By 6-8 weeks of age, Gulo −/− mice were smaller than Gulo +/+ or Gulo +/− littermates and had fewer bone marrow and spleen cells (Extended Data Fig. 3b-d ). In the bone marrow and spleen of Gulo −/− mice, HSC frequency (Fig. 1d , e) and HSC number normalized to body mass (Extended Data Fig. 3e , f) were significantly higher than in littermate controls at 7 and 8 weeks of age. The frequencies of most of the other haematopoietic progenitors, and their rates of cell division, did not significantly differ between Gulo −/− and control mice (Extended Data Fig. 3g-t) . Gulo −/− thymuses were hypocellular (Extended Data Fig. 3u ), consistent with a known requirement for ascorbate in thymocyte maturation 14 . Upon competitive transplantation into irradiated mice, Gulo −/− bone marrow cells showed significantly higher levels of reconstitution of cells in all lineages compared to control cells (Fig. 1f) . Therefore, HSC frequency was significantly higher in ascorbate-depleted mice.
Ascorbate regulates the function of Tet in HSCs
Ascorbate is a cofactor for several α -ketoglutarate-dependent dioxygenases 15 , including Jumonji histone demethylases 16 . However, ascorbate depletion did not significantly increase the levels of several histone methylation marks (Extended Data Fig. 4a ). Although ascorbate promotes the activity of prolyl 4-hydroxylase during collagen synthesis 17 , we did not detect a pronounced loss of bone collagen in ascorbate-depleted mice (Extended Data Fig. 4b ). Nevertheless, a loss of collagen, or collagen organization, may be observed with longerterm ascorbate depletion. Ascorbate can regulate hydroxylase enzymes during carnitine biosynthesis in culture 18 ; however, we did not detect any effect of ascorbate depletion on carnitine or acetylcarnitine levels in haematopoietic cells (Extended Data Fig. 4c ). We also did not detect any effect of ascorbate depletion on levels of reactive oxygen species in haematopoietic cells (Extended Data Fig. 4d ). Ascorbate can act as a cofactor for prolyl hydroxylases that degrade hypoxia inducible factors (HIFs) 19 , but HIF-1α and HIF-2α are not required for HSC function 20 . Despite our inability to detect an effect of ascorbate depletion on the function of these enzymes, they could potentially contribute to the effects of ascorbate depletion on HSCs.
Ascorbate promotes the activity of Tet enzymes in culture 7, [21] [22] [23] , although it remains unclear whether ascorbate limits Tet function in vivo. Tet enzymes convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), and subsequently catalyse some of the steps towards unmethylated cytosine 24, 25 . Mutations that inactivate Tet2 are early events in leukaemogenesis 26 that increase HSC frequency and self-renewal [27] [28] [29] and cause leukaemia when combined with other mutations [30] [31] [32] . Consistent with previous studies [27] [28] [29] , conditional deletion of Tet2 in adult haematopoietic cells significantly increased HSC frequency and function (Extended Data Fig. 5a-h) , similar to what was observed after ascorbate depletion.
To analyse whether physiological variations in ascorbate regulate Tet function in haematopoietic cells, we sustained Gulo −/− mice with low levels of ascorbate in the drinking water for 3-6 months. These mice showed approximately tenfold lower levels of ascorbate in the plasma and in haematopoietic cells relative to littermate controls ( Fig. 2c and Extended Data Figs 4e, 6e, f). Ascorbate levels in Gulo −/− mice were therefore similar to those observed in 5% of people in western countries 33 . Ascorbate-depleted Gulo −/− mice had significantly reduced 5hmC levels in HSCs/MPPs, haematopoietic progenitor cells (HPCs), myeloid progenitors and unfractionated bone marrow cells relative to littermate controls (Fig. 2a) , but they had normal 5mC levels, suggesting that these cells had reduced Tet activity (Fig. 2b) . Similar to ascorbate, 5hmC levels were highest in HSCs/MPPs and these levels decreased with differentiation (Fig. 2a) .
To investigate whether ascorbate regulates 5hmC levels by modulating Tet2 activity, we compared 5hmC levels in haematopoietic cells from Gulo −/− mice, in 
;Tet2
Δ/Δ compound mutant mice did not have significantly lower 5hmC levels compared to the same cells from Tet2 Δ/Δ mice (Fig. 2a) . Therefore, most of the effect of ascorbate depletion on 5hmC levels in HSCs/MPPs and HPCs was mediated by changes in the function of Tet2. Myeloid progenitors did have significantly lower 5hmC levels in Gulo −/−
Δ/Δ compound mutant mice compared to Tet2 Δ/Δ mice (Fig. 2a) . Ascorbate depletion, therefore, reduced 5hmC levels in myeloid progenitors through Tet2-dependent and Tet2-independent mechanisms. The Tet2-independent mechanisms may include effects on the function of Tet1 or Tet3 (Fig. 2a) .
To ascorbate-depleted and littermate-control mice at 6, 7 or 8 weeks of age (n = 6-11 mice per genotype per time point, 3-6 independent experiments per time point). f, Percentage of donor-derived haematopoietic cells after competitive transplantation of 500,000 donor Gulo +/+ or Gulo −/− bone marrow cells along with 500,000 competing wild-type recipient cells into irradiated recipient mice (a total of three donors and 14-15 recipients per genotype for three independent experiments). The exact number of mice analysed and the values obtained for each mouse are provided in the Source Data. Statistical significance was assessed with t-tests (b, c) or two-way ANOVAs followed by Fisher's least significant difference (LSD) tests for individual time points (d-f). All data represent mean ± s.d. We corrected for multiple comparisons by controlling the false discovery rate. * P < 0.05, * * P < 0.01, * * * P < 0.001.
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after transplantation (Extended Data Fig. 6a, c, d ). Tet2-deficient HSCs transplanted into wild-type recipients gave significantly higher levels of reconstitution than wild-type HSCs, as expected, but this effect was attenuated in ascorbate-depleted Gulo −/− recipients (Extended Data Fig. 6d ). The increase in HSC function by ascorbate depletion is, therefore, mediated in part by Tet2, because ascorbate depletion increased cell reconstitution more from the wild-type competitor cells than from Tet2-deficient HSCs.
Supplementation with higher levels of dietary ascorbate (ascorbate repletion) increased ascorbate levels in Gulo −/− mice to those observed in wild-type mice (Extended Data Fig. 6e, f) . This prevented the decrease in 5hmC levels in HSCs and restricted progenitors (Fig. 2d, e) as well as the increase in HSC frequency and function (Fig. 2f, g ). Therefore, these phenotypes are caused by ascorbate depletion.
Addition of ascorbate to cultured HSCs significantly reduced monocytic differentiation and promoted erythroid differentiation (Extended Data Fig. 6g-m) . This is consistent with the conclusion that ascorbate promotes Tet2 function, because Tet2 deficiency promotes monocytic differentiation and reduces erythroid differentiation in culture 28, 34 . We performed RNA-sequencing analysis in HSCs/MPPs from Gulo
Δ/Δ and control mice and found that some of the changes in gene expression in ascorbate-depleted HSCs/ MPPs were also observed in Tet2-deficient HSCs/MPPs (Extended Data  Fig. 7 ). The number of transcripts in Gulo −/− and Tet2 Δ/Δ HSCs/MPPs that changed in the same direction relative to control HSCs/MPPs was significantly higher than expected by chance and included regulators of haematopoiesis, cell death and differentiation (Extended Data Fig. 7b) . A common group of gene sets were downregulated in both Gulo −/− and Tet2 Δ/Δ HSCs/MPPs (Extended Data Fig. 7c ).
Ascorbate depletion cooperates with Flt3(ITD)
TET2 mutations cooperate with FLT3 ITD mutations to cause acute myeloid leukaemia (AML) 31, 35 . Consistent with this, Tet2 deficiency and Flt3 ITD mutations cooperated to significantly increase the frequencies of HPCs and some of the myeloid progenitors (Extended Data Fig. 8a-f 
and Tet2 Δ/Δ ;Gulo −/− (n = 8 mice) mice from 10 independent experiments. * Comparisons between genotypes and #comparisons between cell types; #P < 0.05, ##P < 0.01, ###P < 0.001; * P < 0.05, * * P < 0.01, * * * P < 0.001. c, Ascorbate levels in cells from four-month-old mice (a total of n = 4 mice per condition from two independent experiments). d, e, 5hmC:5mC and 5mC:C ratios in sorted cell populations from four-month-old mice with or without ascorbate feeding (a total of n = 4 mice per condition from three independent experiments). f, HSC frequency in eight-week-old mice (a total of n = 8-11 mice per genotype from six independent experiments). g, Percentage of donor-derived haematopoietic cells after competitive transplantation of 500,000 donor bone marrow cells from Gulo +/+ or Gulo −/− mice, or Gulo −/− mice supplemented with ascorbate, along with 500,000 competitor wild-type cells in irradiated recipient mice (a total of four donors and 19-20 recipients per genotype from four independent experiments). Statistical significance was assessed with one-way (a, b, d-f) or two-way (c) ANOVAs, Kruskal-Wallis tests (for abnormally distributed data in a, b), or with a non-parametric mixed model followed by KruskalWallis tests for individual time points (g). All data represent mean ± s.d. We corrected for multiple comparisons by controlling the false discovery rate. * P < 0.05, * * P < 0.01, * * * P < 0.001.
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depleted while other cells in the recipient mice had normal ascorbate levels (Extended Data Fig. 8i ). The Slc23a2 −/− cells showed significantly higher levels of cell reconstitution compared to control cells in all lineages, except the T cell lineage (Fig. 3g) . Slc23a2 −/− cells also gave rise to higher levels of myelopoiesis compared to control cells (Extended Data  Fig. 8j Fig. 4g ) and had significantly more myeloblasts, WBCs, myeloid cells in their blood, and HPC cells in their spleen (Fig. 4h-j and Extended Data Fig. 10a ). Therefore, ascorbate depletion accelerates leukemogenesis partly through Tet2-independent mechanisms that may include regulation of Tet1 or Tet3 (Fig. 4e) . We did not detect significant changes in histone methylation markers in leukaemia cells from ascorbate-depleted compared to wild-type mice (Extended Data Fig. 10c) . However, ascorbate depletion may promote a, b, e, g ), one-way ANOVAs followed by Fisher's LSD tests (between genotypes in c, d) and Mann-Whitney U-tests (between donor and competitor in c, d). We corrected for multiple comparisons by controlling the false discovery rate. * P < 0.05, * * P < 0.01, * * * P < 0.001; #P < 0.05, ##P < 0.01, ###P < 0.001; †P < 0.05, † †P < 0.01, † † †P < 0.001.
Article reSeArcH leukaemogenesis in part by regulating histone demethylases or other dioxygenase enzymes, or through non-cell-autonomous effects on the microenvironment. The relative contribution of Tet2-dependent and Tet2-independent mechanisms to leukemogenesis remains unclear.
We next investigated whether leukaemia progression in an ascorbatedepleted environment can be reversed by dietary ascorbate. Normal ascorbate levels in Gulo −/− mice were restored by ascorbate supplementation, starting 6-7 weeks after transplantation (Fig. 5a ), when leukaemia was already histologically evident (Fig. 4) . Feeding with ascorbate significantly extended survival (Fig. 5b) , while significantly reducing myeloblasts in the blood, spleen cellularity and HPC frequency in the spleen (Fig. 5c-e and Extended Data Fig. 10d-f) .
To test whether our findings are relevant to humans, we measured ascorbate levels in human haematopoietic cells from fresh adult bone marrow biopsies. Similar to mouse HSCs, human HSCs/MPPs had significantly higher levels of ascorbate ( Fig. 5f ) and SLC23A2 expression (Fig. 5g) compared to other haematopoietic cells, and SLC23A1 expression was not detected. Ascorbate levels in human HSCs (Fig. 5f ) were similar to those in mouse HSCs (Fig. 2c) .
Addition of ascorbate to the culture medium promotes pluripotency by stimulating Jumonji histone demethylase activity 16 and by stimulating Tet activity 7, 22 . Our results do not address the biochemical mechanism by which ascorbate regulates Tet function, but extend the data from cultured cells by showing that physiological variations in ascorbate levels within tissues regulate stem-cell function and cancer initiation.
In western countries, plasma ascorbate levels vary tenfold among individuals 33 , and the lowest quartile of men have a significantly higher risk of mortality from cancer 38, 39 . Humans with haematological malignancies have substantially lower serum ascorbate levels as compared to healthy controls 40, 41 . In clinical trials, oral ascorbate administration failed to benefit patients with established cancers 42 , although supraphysiological ascorbate concentrations can slow the growth of some cancers in mice by causing oxidative stress 43, 44 . Moreover, clonal haematopoiesis of indeterminate potential is common among older humans and is often associated with loss of one Tet2 allele [45] [46] [47] . Our data suggest that it is important for people with clonal haematopoiesis to get adequate dietary ascorbate to maximize the residual tumour-suppressor function of Tet enzymes.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. . e-j, Eight million bone marrow cells from donor mice of the indicated genotypes were transplanted into irradiated wild-type or ascorbate-depleted Gulo −/− recipient mice and analysed 6-8 weeks after transplantation (a total of four donors and 8-19 recipients per treatment from four independent experiments). e, f, 5hmC:5mC and 5mC:C ratios in donor cells from bone marrow of transplant recipients (a total of n = 6 mice per treatment from six independent experiments). g, Kaplan-Meier survival curve of transplant recipients (four independent experiments, Mantel-Cox log-rank test). h-j, Analysis of the blood or spleen of transplant recipients. Statistical significance was assessed with one-way ANOVAs followed by Fisher's LSD tests (c-f, i, j) or Kruskal-Wallis tests (a, h). All data represent mean ± s.d. We corrected for multiple comparisons by controlling the false discovery rate. * P < 0.05, * * P < 0.01, * * * P < 0.001. ITD or wild-type donor mice were transplanted into irradiated wild-type or Gulo −/− recipient mice. Some Gulo −/− recipients were fed with ascorbate before (pre-leukaemia) or 6-7 weeks after transplantation (post-leukaemia) (a total of n = 3 donors with 5-13 recipients per treatment from four independent experiments). Mice were analysed 10-11 weeks after transplantation. b, Kaplan-Meier survival curve of transplant recipients of Tet2 Δ/+ ;Flt3 ITD cells treated (six independent experiments, Mantel-Cox log-rank test). f, g, Ascorbate levels and SLC23A2 expression in human bone marrow haematopoietic cells (see Methods for the markers used to isolate each cell population. f, A total of n = 7 samples analysed from seven independent experiments. g, A total of n = 5 samples analysed from five independent experiments). Statistical significance was assessed with t-tests (g), one-way ANOVAs followed by Fisher's LSD tests (d, f) or Kruskal-Wallis tests (c, e). We corrected for multiple comparisons by controlling the false discovery rate. All data represent mean ± s.d. * P < 0.05, * * P < 0.01, * * * P < 0.001. Supplementary Information is available in the online version of the paper. ;Mx1-cre mice were injected with five intraperitoneal injections of 20 μ g poly(I:C) (GE Healthcare) every other day at 6-8 weeks of age to induce Cre expression. Ascorbate-depleted Gulo −/− mice analysed at 6-8 weeks of age were weaned at four weeks of age and then fed a standard mouse diet, which contains little ascorbate. Ascorbate-depleted Gulo −/− mice maintained for longer than eight weeks were fed a 1% ascorbate diet (Harlan) from the time of weaning until 6-8 weeks of age, then switched to a standard mouse diet and provided with 100 mg l −1 of ascorbate in the drinking water, changed twice per week. This regimen resulted in ascorbate-depleted mice that could be maintained for at least eight months. Ascorbate-replete Gulo −/− mice were fed an ascorbate-supplemented diet (a 1% ascorbate diet (Harlan)) from the time of weaning onwards, or as indicated in the text. For the experiments in Fig. 4a-d Table 1 . Lineage markers for HSCs and progenitors were CD3, CD5, CD8, B220, Gr-1 and Ter119. Antibody staining was performed at 4 °C for 30 min, or, when CD34 was included in the cocktail, on ice for 90 min. Biotinylated antibodies were visualized by incubation with PE-Cy7-, BV510-or BV421-conjugated streptavidin at 4 °C for 30 min. 4′ ,6-diamidino-2-phenylindole (DAPI; 2 μ g ml −1 in phosphate buffered saline (PBS)) or propidium iodide (1 μ g ml ) were used to exclude dead cells during flow cytometry. All reagents were acquired from BD Biosciences, eBiosciences, BioLegend or Tonbo. For isolation of all Kit + cell populations, cells were pre-enriched before flow cytometry using paramagnetic microbeads and an autoMACS magnetic separator (Miltenyi Biotec). Analysis and cell sorting were performed using a FACSAria flow cytometer (BD Biosciences) or a BD FACSCanto (BD Biosciences). Data were analysed using FACSDiva (BD Biosciences). Cell isolation for metabolomics. Methods for the isolation of cells for metabolomics were optimized for speed and to keep the cells cold at all times, to minimize metabolic changes during isolation. Mice were euthanized by cervical dislocation and bone marrow cells were obtained by crushing femurs, tibias, vertebrae and pelvic bones with an ice-cold mortar and pestle in a 4 °C cold room or on ice in 2 ml of Ca
2+
-and Mg
-free HBSS, supplemented with 0.5% bovine serum albumin. Cells were filtered through a 40-μ m cell strainer or a 45-μ m nylon mesh into 5-ml tubes on ice. For sorting haematopoietic stem and progenitor cells, paramagnetic MicroBeads against Kit (Miltenyi) were added to each sample, followed 1 min later by all of the antibodies used for the isolation of the relevant cell populations (as indicated). Fluorochrome-conjugated antibodies were used in all cases to enable a single staining step. For experiments in which CD45
+ bone marrow cells were isolated, paramagnetic MicroBeads against CD45 (Miltenyi) were used to preenrich, followed 1 min later by the other antibodies required to isolate the other cell populations in the experiment. Antibody staining was for 30 min on ice in a 4 °C cold room, with occasional mixing. Then Kit + cells or CD45 + cells were enriched using a QuadroMACS manual separator (Miltenyi) in the cold room. For most experiments, four mice were analysed in parallel, in which case the total time from killing the first mouse to the completion of cell isolation was 2-3 h, during which time the samples were kept on ice as each sample was processed. Control experiments showed that incubation for up to 7 h on ice did not significantly change the levels of most of the metabolites that we detected in bone marrow cells (Extended Data Fig. 1b ). Cells were sorted on a FACSAria flow cytometer running with a sheath fluid of 0.5× PBS, prepared fresh using Milli-Q water (Millipore), and a 70-μ m nozzle in a four-way purity sort mode to minimize the volume of sorted drops, so as to eliminate ion suppression of mass spectrometry signals from salts in the sheath fluid. The FACSAria sheath tank was washed with Milli-Q deionized water before the experiment to eliminate contaminants and dedicated glassware was used to make all buffers. Each sample was in HBSS + 0.5% BSA and kept at 4 °C during sorting, which lasted about 20 min per sample. Equal numbers of cells from each population were directly sorted in each experiment (usually 5,000-20,000 cells) into 500 μ l of cold 80% methanol pre-chilled on dry ice and maintained at 4 °C during sorting. No serum was used during the procedure. After sorting, each sample was kept on dry ice for the duration of the experiment, and then stored at − 80 °C. Metabolite extraction and metabolomics. Samples in 80% methanol were vortexed for 1 min to lyse the cells, then centrifuged at 17,000g for 15 min at 4 °C. To measure ascorbate, 15 pmoles 13 C-ascorbate (Sigma-Aldrich) was added to the 80% methanol as an internal standard and 1 mM EDTA was added to prevent ascorbate oxidation 52 . Cell extracts were centrifuged immediately after cell isolation. The supernatant was transferred to a new tube and lyophilized using a Speedvac (Thermo Scientific). Dried metabolites were reconstituted in 30 μ l of 0.03% formic acid, vortexed, centrifuged at 17,000g for 15 min at 4 °C and the supernatant was analysed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). For experiments in which ascorbate was measured in cells, dried metabolites were reconstituted in 30 μ l of 0.03% formic acid + 1 mM EDTA. For experiments in which ascorbate was measured in the plasma, four volumes of 90% methanol + 1 mM EDTA + 13 C-ascorbate on dry ice were added to one volume of plasma, vortexed, centrifuged at 17,000g for 15 min at 4 °C and the supernatant analysed by LC-MS/MS. A Nexera Ultra High Performance Liquid Chromatograph (UHPLC) system (Shimadzu) was used for liquid chromatography, with a Polar-RP HPLC column (150 × 2 mm, 4 μ m, 80 Å, Phenomenex) and the following gradient: 0-3 min 100% mobile phase A; 3-15 min 100-0% A; 15-17 min 0% A; 17-18 min 0-100% A; 18-23 min 100% A. Mobile Phase A was 0.03% formic acid in water. Mobile Phase B was 0.03% formic acid in acetonitrile. The flow rate was 0.5 ml min −1 , the column was at 35 °C and the samples in the autosampler were at 4 °C. Mass spectrometry was performed with a triple quadrupole mass spectrometer (AB Sciex QTRAP 5500) in multiple reaction monitoring (MRM) mode as described 53 , with some modifications. Transitions that never gave a signal in extracts from 20,000 cells were omitted from the MRM list. For experiments to detect ascorbate, the dwelling time for ascorbate and 13 C-ascorbate was increased to 50 ms. Chromatogram peak areas were integrated using Multiquant (AB Sciex). For analysis, the peak area for each metabolite was normalized to the median peak area of the sample. For hierarchical clustering, only metabolites that were detected in every cell population were used. Metabolomics data analysis and hierarchical clustering were performed using MetaboAnalyst 54 and Simca (Umetrics). Measurement of 5hmC, 5mC and C by LC-MS/MS. To measure modified cytosines in purified populations, cells were sorted by flow cytometry into Ca 2+ and Mg 2+ free HBSS + 2% heat inactivated bovine serum, washed once with ice cold normal saline, and the genomic DNA was purified using the QIAamp micro kit (Qiagen) according to the manufacturer's instructions. To measure modified cytosines in unfractionated bone marrow, 5 million fresh bone marrow cells were pelleted, washed once with ice cold normal saline and genomic DNA was purified using the DNeasy blood and tissue kit (Qiagen) according to the manufacturer's instructions. Total genomic DNA from sorted cells, or 1 μ g of DNA from unfractionated bone marrow, was digested to nucleosides with DNA Degradase Plus (Zymo Research), according to the manufacturer's instructions, with the following internal standards added to the mix: -5mdC) , D3-5-hydroxymethyl-2-deoxycytidine (D3-5hmdC) (Toronto Research Chemicals). Samples were then filtered with a 10 kDa Amicon column (Millipore) to remove enzymes, and filtrates were analysed by LC-MS/MS. Liquid chromatography was carried out with a Waters Atlantis or a Scherzo SM-C18 (Imtakt) reverse phase C18 column, 3 μ m, 2.1 × 100 mm. Mobile phase A was 0.1% formic acid in water, and mobile phase B was 0.1% formic acid in acetonitrile. The gradient was: 0-2.5 min 0% B; 2.5-5 min 0-100% B; 5-6 min 100% B; 6-7 min 100-0% B; 7-9 min 0% B. The flow rate was 0.5 ml min −1
. The flow was diverted to the waste for the first 0.9 min. The column was at 35 °C and the samples in the autosampler were at 4 °C. Mass spectrometry was performed with an AB Sciex QTRAP 5500 operating in MRM mode. Mass spectrometry parameters were optimized using pure standards for 2-deoxycytidine (2dC), 5-methyl-2-deoxycytidine (5mdC) and 5-hydroxymethyl-2-deoxycytidine (5hmdC) (Berry and Associates). The following transitions were monitored in positive mode: 2dC 228.1/112.1; 5mdC 242.1/126.1; 5hmdC 258.1/142.1; Chromatogram peak areas were integrated using Multiquant (AB Sciex). The amount of each nucleoside in a sample was calculated by dividing the peak area of the unlabelled endogenous nucleoside by the peak area of the labelled internal standard. Bone marrow reconstitution assays. Recipient mice (CD45.1) were irradiated using an XRAD 320 X-ray irradiator (Precision X-Ray Inc.) with two doses of 540 rad (1,080 rad in total) delivered at least 3 h apart. Cells were injected into the retro-orbital venous sinus of anaesthetized recipients. For competitive transplants, mixed donor (CD45.2) and competitor (either CD45.1 or CD45.1/CD45.2) cells were transplanted. After transplantation, mice were maintained on antibiotic water (Baytril 0.08 mg ml BrdU incorporation analysis. Mice were injected with a single dose of 5-bromo-2′ -deoxyuridine (BrdU; 1 mg per 10 g body mass) and maintained on 1 mg BrdU per ml drinking water for three days. Then HSCs or MPPs were isolated as described above, fixed, and stained using the BrdU APC Flow Kit (BD Biosciences) and analysed for BrdU incorporation. For the other cell populations analysed, which are more abundant than HSCs and MPPs, cells were stained with cell surface antibodies, then fixed and stained using the BrdU APC Flow Kit (BD Biosciences) and analysed for BrdU incorporation. Human haematopoietic cell purification. Bone marrow aspirates were collected from patients, aged 34-85, who were being assessed for lymphoma, for whom no evidence of lymphoma or myelodysplastic syndrome was observed. Each sample was obtained from a different patient. Following diagnosis, aspirates were stained using antibodies against CD34 (4H11, APC-conjugated), CD45RA (HI100, PE-conjugated), CD38 (HIT2, PECy7-conjugated), and Lineage markers (CD2, CD3, CD14, CD16, CD19, CD56, CD235A, Thermo Fisher, FITC-conjugated). The cells were purified within 1-2 days of the biopsy. Prior to purification, bone marrow aspirates were kept at 4 °C in RPMI medium. The cell populations shown in Fig. 5 were isolated with the following markers: Lin fl/fl and Flt3 ITD genotyping were as previously described 27, 49 . For qPCR, cells were sorted into RLT buffer (Qiagen RNAeasy Micro kit) and RNA was purified according to the manufacturer's instructions. cDNA was made with iScript reverse transcriptase (BioRad) and quantitative PCR was performed with iTaq Universal SYBR Green (BioRad) and a LightCycler 480 (Roche Applied Science). The signal from each sample was normalized to β -actin. qPCR primers: mouse Slc23a2: 5′ -GGACAACACCATCCCAGGTA-3′ , 5′ -CCTTTGCTCACACCCTTCTT-3′ . Mouse Slc23a1: 5′ -GAAGCCACCTCAAT GAAAGG-3′ , 5′ -GCTGAGATCTCCAACTCAGGTC-3′ . Mouse β -actin (Actb): 5′ -CACTGTCGAGTCGCGTCC-3′ , 5′ -TCATCCATGGCGAACTGGTG-3′ .
Human SLC23A2: 5′ -CTGCAGCCAGCTAGGTCTTG-3′ , 5′ -AAGCTAGG AGCCCAGGATCA-3′. Human SLC23A1: 5′ -TCCTCCTCCTTGGCCTTTGT-3′ , 5′ -CCCTGGTGGTTTCATGCTGT-3′. Human β -Actin (ACTB): 5′ -ATTGG CAATGAGCGGTTC-3′ , 5′ -CGTGGATGCCACAGGACT-3′. RNA-sequencing (RNA-seq) analysis. Cells were sorted into RLT buffer (Qiagen RNAeasy Plus Micro kit) and RNA was purified according to the manufacturer's instructions. RNA quality was validated using a Pico Bioanalyzer. RNA sequencing libraries were generated using the SMARTer Stranded Total RNA-Seq kit, Pico Input Mammalian (Clonetech). Library fragment size was measured using D1000 Screen Tape (Agilent) and library concentration was measured using the Qubit RNA assay kit (Life Technologies). Libraries were sequenced using the Illumina NextSeq 500 desktop Next Generation Sequencing system. The quality of RNA-seq raw reads was checked using FastQC v.0.11.2. Raw reads were quality-trimmed using Trimmomatic v.0.32 and mapped to the mouse genome, GRCm38, using TopHat v.2.0.12 with Bowtie2 v.2.2.3. Mapped reads were quality-filtered using SAMtools v.0.1.19, and quantified using HTSeq v.0.6.1. Differential expression was assessed using DESeq2 v.1.8.2 and RUVSeq v.1.2.0 with R v.3.2.1. A fold-change heat map was generated using Cluster 3.0. Computational analysis was performed using the BioHPC high-performance computing cluster at UTSW. HSC culture. 10 HSCs per well were sorted into a 96-well plate containing IMDM with 10% fetal bovine serum, 50 ng ml −1 SCF, 10 ng ml −1 TPO, 10 ng ml −1 IL-3 and 4 ng ml −1 IL-6. For experiments that assessed erythroid differentiation (Extended Data Fig. 6m ), 2 U ml −1 EPO was included. Ascorbate or 2-phospho-ascorbate (Sigma-Aldrich) were used at 50 μ g ml −1 . The culture medium was changed every two days. Eight days after plating, cells were stained and analysed by flow cytometry. Histology. Routine histological processing of tissue specimens was performed at the UTSW Molecular Pathology Core. Sirius red and Masson's trichrome stains on paraffin bone sections were performed according to the supplier's instructions (IHCWorld). With Sirius red, collagen is stained red with bright field imaging, and stained red or green with polarized light imaging. With Masson's trichrome, collagen is stained blue. Blood smears were stained with Diff-Quik. Peripheral blood was subjected to an automated complete blood count, and, where indicated, a manual WBC differential was performed by a haematopathologist (G. Protein extraction and western blot analysis. Equal numbers of cells from each population were sorted into trichloroacetic acid (TCA, Sigma-Aldrich), and the TCA final concentration was adjusted to 10%. Samples were centrifuged at 16,000g for 15 min, and precipitates were washed twice with cold acetone and dried. Samples were solubilized in 9 M urea, 2% Triton X-100, 1% DTT. LDS loading buffer (Life Technologies) was added. Samples were heated at 70 °C for 10 min, separated on NuPAGE Bis-Tris polyacrylamide gels (Life Technologies), and transferred to 0.2 μ m PVDF membranes (BioRad) by wet transfer using NuPAGE transfer buffer (Life Technologies). Western blots were performed using antibodies against β -actin (AC-74, Sigma-Aldrich), histone H3 (polyclonal, Abcam, ab1791), H3K4me3 (C42D8, Cell Signaling), H3K27me3 (C36B11, Cell Signaling), H3K4me2 (C75H12, Cell Signaling) and H3K36me2 (C64G9, Cell Signaling). For low numbers of cells (7,000-15,000), the SuperSignal Western Blot Enhancer kit (Thermo Scientific) was used according to the manufacturer's instructions. Signals were detected using the SuperSignal West Pico or SuperSignal West Femto chemiluminescence kits (Thermo Scientific). Blots were stripped with 0.2 N NaOH and/or 1% SDS, 25 mM glycine, pH = 2 before re-probing. Statistical methods. Most figure panels contain data from multiple independent experiments performed on different days. Data represent mean ± standard deviation, except when data are presented as fold-change values, in which case the geometric mean ± geometric standard deviation is shown. Numbers of experiments noted in figure legends reflect independent experiments that were almost always performed on different days. The sample size used in each experiment was not predetermined or formally justified for statistical power. For samples with low variation, for example, metabolite levels in HSCs, 4-6 samples per condition were analysed in each experiment. For samples with large variation, for example, transplantation experiments, 15-20 samples per condition were analysed in each experiment. Blinding was not used in experiments. Mice were allocated to experiments randomly and samples processed in an arbitrary order, but formal randomization techniques were not used.
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Prior to analysing the statistical significance of differences among treatments we tested whether data were normally distributed and whether variance was similar among treatments. To test for normality, we performed the D' Agostino-Pearson omnibus test for sample sets with n > 8 or the Shapiro-Wilk normality test for smaller sample sets. To test whether variability significantly differed among treatments we performed F-tests (for experiments with two treatments) or Levene's median tests (for experiments with more than two treatments). When the data significantly deviated from normality (P < 0.01) or variability significantly differed among treatments (P < 0.05), we log 2 -transformed the data and tested again for normality and variability. If the transformed data no longer significantly deviated from normality and equal variability, we then performed parametric tests on the transformed data. If the transformed data still significantly deviated from normality or equal variability, we performed non-parametric tests on the non-transformed data.
To assess the statistical significance of a difference between two treatments, we used two-tailed Student's t-tests (when a parametric test was appropriate), Mann-Whitney U-tests (when the data in any treatment significantly deviated from normality) or Welch's tests (when the data were normally distributed, but variances were unequal among treatments). To assess the statistical significance of differences between more than two treatments, we used one-way or two-way ANOVAs (when a parametric test was appropriate; two-way ANOVAs were used when the experiment involved multiple genotypes as well as multiple time points or multiple cell populations) or Kruskal-Wallis tests (when the data in any treatment significantly deviated from normality or variances were unequal among treatments).
For ANOVAs in which a minority of samples significantly diverged from normality or equal variance, ANOVAs were used followed by Mann-Whitney U-tests or Kruskal-Wallis tests for comparisons that involved the abnormal groups. To test overall differences among genotypes in transplantation experiments, we used either a mixed two-way ANOVA in which data from the same mouse across time points were taken as repeated measurements (when data were normally distributed and equally variable), or a non-parametric mixed model statistical method, nparLD 57 (when some of the data significantly deviated from normality or equal variability). To confirm the results of the nparLD method, we also performed mixed two-way ANOVAs. Differences that were significant by the nparLD method were almost always significant by the mixed two-way ANOVA. We always corrected for multiple comparisons using the false discovery rate method with the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli.
The statistical significance of differences in survival was assessed using the Mantel-Cox log-rank test. The statistical significance of differences in fold-change values was assessed using log 2 -transformed data. For analysis of metabolomics data, the raw value for each metabolite was normalized to the median metabolite value in each sample. Normalization to the average metabolite value of each sample was also performed to ensure relative values between samples were consistent, independent of the mode of normalization. All statistical analyses were performed with Graphpad Prism software with the exception of the nparLD test, which was performed with R v.3.2.1.
The only mice excluded from experiments were transplant recipients that had no donor cell reconstitution in Fig. 3e and Extended Data Fig. 8g . Because only 1 in 37,000 whole bone marrow cells in wild-type mice is an HSC 58 , and HSC frequency in Flt3 ITD mice was 5-10-fold lower than in wild-type mice (Extended Data Fig. 8a ), it was expected that some recipients of 300,000 (Extended Data Fig. 8g ) or 500,000 (Fig. 3e) whole bone marrow cells from these genotypes would receive no HSCs. Therefore, for purposes of comparing donor cell reconstitution levels among treatments, we only included recipient mice with at least 1% donor cell reconstitution, and excluded recipients with < 1% donor cell reconstitution (6 
;Flt3
ITD to Gulo −/− recipients were excluded from the experiment in Fig. 3e ). In Fig. 5f , samples from one patient were excluded, because of evidence of myelodysplastic syndrome. In Extended Data Fig. 6d, data and after the engraftment of leukaemia cells (representative images from the experiments described in Fig. 5a and quantified in Fig. 5c ). Cells with an immature blast-like morphology were more abundant in the blood of ascorbate-depleted Gulo −/− recipients compared to ascorbate-fed Gulo
recipients. e, f, WBCs in recipient mice from the experiment described in Fig. 5a . The statistical significance of differences among treatments was assessed with Kruskal-Wallis tests (a, e, f) or a one-way ANOVA (b) or a two-way ANOVA followed by Fisher's LSD tests (c). All data represent mean ± s.d. We corrected for multiple comparisons by controlling the false discovery rate. * P < 0.05, * * P < 0.01, * * * P < 0.001. 
Data exclusions
Describe any data exclusions.
In Figure 5f , data from 1 human patient was excluded due to clinical evidence of myelodysplastic syndrome. In Figures 3e and ED Figure 8g , some recipient mice were excluded because they showed no reconstitution, suggesting no HSCs were present among the donor cells, therefore those samples provided no information on HSC activity. In ED Figure 6d , time point 4 was excluded from the statistical analysis because it involved comparisons between genotypes before Tet2 conditional deletion.
Replication
Describe whether the experimental findings were reliably reproduced.
The experimental findings were reproduced in multiple independent experiments. The number of independent experiments and biological replicates in each data panel is indicated in the figure legends. Data shown in the figures represent the aggregate of all independent experiments in almost all cases. Data shown in a minority of panels are from a representative experiment (e.g. western blots) and in those cases the number of independent experiments that reproduced the finding is also indicated in the figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No formal randomization techniques were used, however, samples were allocated randomly into experimental groups and processed in an arbitrary order.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to group allocation during data collection and analysis nature research | life sciences reporting summary June 2017
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There are no restrictions on the availability of materials. No unique materials were used in this study. Antibodies and chemical reagents were purchased from forprofit companies as detailed in the methods.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). No cell lines were used
